Mr Khalid Beshir

Associate Professor

United Kingdom

Dr Beshir is a genomic epidemiologist with a background in Biology, Medical Parasitology and Biomedical Science.

Dr Beshir's research work focuses on understanding how malaria parasites evade drug attack (become resistant) and escape detection by rapid diagnostic tests (RDTs)and become undetectable. To achieve this, we continuously work on the development of new and fit-for-purpose molecular and genomic tools to detect and monitor these new malaria parasite population. Dr Beshir has previously worked on the development of affordable COVID-19 testing assays that can be used in Low and Middle Income Countries, and supported LMIC countries with COVID-19 vaiant detections using NGS genomics.

Dr Beshir previously worked on EDCTP-funded WANECAM project on Clinical trial of four Artemisinin Combination Therapies (ACT) in west Africa. Dr Beshir also worked on molecular evaluation of the efficacy of ACTs as well as Seasonal Malaria Chemoprevention (SMC) therapies in West Africa. In both projects, Dr Beshir worked on development of new molecular tools to monitor the emergence of drug resistance parasites to both ACTs and SMCs.

Dr Beshir is also involved in teaching both within LSHTM and externally, and supervision of MSc and PhD students. Dr Beshir is also a member of LSHTM ethics commitee and member of EDI in ITD Faculty.

Dr Beshir completed his PhD in Prof Sutherland's group.


Department of Infection Biology
Faculty of Infectious and Tropical Diseases


Malaria Centre


Dr Beshir teaches molecular and genomic evolution, and he is a tutor on Medical Parasitology course and Malaria DL module. Dr Beshir is involved in teaching of Miscroscopic Diagnosis of Malaria Parasites and Molecular Biology. Dr Beshir is a member of joint committee for Medical Parasitology and Medical Entomology for Disease Control courses.


Research Area
Drug resistance
Molecular epidemiology
Disease and Health Conditions
Burkina Faso
Cote d'Ivoire
Democratic Republic of the Congo
Sub-Saharan Africa (all income levels)

Selected Publications

Measuring protective efficacy and quantifying the impact of drug resistance: A novel malaria chemoprevention trial design and methodology.
MOUSA, A; Cuomo-Dannenburg, G; Thompson, HA; CHICO, RM; BESHIR, KB; Sutherland, CJ; SCHELLENBERG, D; GOSLING, R; Alifrangis, M; Hocke, EF; Hansson, H; Chopo-Pizarro, A; Mbacham, WF; Ali, IM; CHAPONDA, M; ROPER, C; Okell, LC;
PLoS medicine
Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
VAN SCHALKWYK, DA; PRATT, S; Nolder, D; Stewart, LB; Liddy, H; MUWANGUZI-KARUGABA, J; BESHIR, KB; Britten, D; Victory, E; Rogers, C; Millard, J; Brown, M; Nabarro, LE; Taylor, A; Young, BC; Chiodini, PL; SUTHERLAND, CJ;
Clinical Infectious Diseases
Rapid profiling of Plasmodium parasites from genome sequences to assist malaria control.
PHELAN, JE; Turkiewicz, A; Manko, E; THORPE, J; VANHEER, LN; Van de Vegte-Bolmer, M; Ngoc, NT H; Binh, NT H; Thieu, NQ; Gitaka, J; Nolder, D; BESHIR, KB; Dombrowski, JG; Di Santi, SM; Bousema, T; SUTHERLAND, CJ; CAMPINO, S; CLARK, TG;
Genome medicine
The spread of a validated molecular marker of artemisinin partial resistance<i>pfkelch13</i>R622I and association with<i>pfhrp2/3</i>deletions in Eritrea
Mihreteab, S; Anderson, K; Molina - de la Fuente, I; SUTHERLAND, C; Smith, D; Cunningham, J; BESHIR, K; Cheng, Q;
Estimating the impact of Plasmodium falciparum dhfr and dhps mutations on protective efficacy of sulfadoxine-pyrimethamine: evidence from therapeutic efficacy studies and implications for malaria chemoprevention
MOUSA, A; Cuomo-Dannenburg, G; Thompson, HA; Bell, DJ; D’Alessandro, U; Nahum, A; Barnes, KI; Raman, J; GOSLING, R; Alifrangis, M; Hocke, EF; Hansson, HS; BESHIR, K; CHICO, RM; SUTHERLAND, CJ; Chopo-Pizzaro, A; Okell, LC; ROPER, C;
72st Annual Meeting of the American Society of Tropical Medicine and Hygiene
Baseline prevalence of molecular marker of sulfadoxine/pyrimethamine resistance in Ebonyi and Osun states, Nigeria: amplicon deep sequencing of dhps-540.
Olukosi, AY; Ajibaye, O; Omoniwa, O; ORESANYA, O; Oluwagbemiga, AO; Ujuju, C; Ekholuenetale, M; MAXWELL, K; SUTHERLAND, CJ; Tibenderana, JK; BESHIR, KB;
The Journal of antimicrobial chemotherapy
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.
BESHIR, KB; Muwanguzi, J; Nader, J; MANSUKHANI, R; Traore, A; Gamougam, K; Ceesay, S; Bazie, T; Kolie, F; Lamine, MM; CAIRNS, M; SNELL, P; SCOTT, S; Diallo, A; Merle, CS; NDiaye, JL; Razafindralambo, L; Moroso, D; Ouedraogo, J-B; Zongo, I; Kessely, H; Doumagoum, D; BOJANG, K; Ceesay, S; Loua, K; ... SUTHERLAND, CJ.
The Lancet Infectious diseases
Designing chemoprevention trials to measure protective efficacy and effects of resistance: insights from simulation
MOUSA, A; ROPER, C; Thompson, HA; BESHIR, K; CHICO, RM; Cuomo-Dannenburg, G; Gosling, R; SUTHERLAND, C; Okell, L;
ASTMH Annual Meeting
Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana.
Paris, L; Tackie, RG; BESHIR, KB; Tampuori, J; Awandare, GA; Binka, FN; Urban, BC; Dinko, B; SUTHERLAND, CJ;
Parasite epidemiology and control
See more information